Cook's permanent vena cava filter:
This article was originally published in Clinica
Cook Medical has received US FDA 510(k) clearance to market its permanently implanted vena cava filter for capturing blood clots caused by medical conditions such as trauma and surgery before they can reach the lungs and cause a pulmonary embolism. The device, called Celect, was last year approved for permanent and retrieval indications in Canada, Australia and Europe. Trials are currently underway to study other aspects of the product, including its retrievability, said the Bloomington, Indiana firm. Celect employs a conical shape with a strut design that improves centering in the vessel and reduces in-growth, except at the desired end points.
You may also be interested in...
Companies across Europe are dealing with new challenges stemming from the coronavirus outbreak, particularly with supply issues due to increased demand. This article details the responses of five consumer health players in the region: Reckitt Benckiser, Zentiva, Vitabiotics, Alliance Pharma and BioGaia.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.